Carbamylated erythropoietin ameliorates cyclosporine nephropathy withoutstimulating erythropoiesis
| Project/Area Number |
22591806
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
YAZAWA Koji 大阪大学, 医学系研究科, 助教 (40569109)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TAKAHARA Shiro 大阪大学, 大学院・医学系研究科, 寄付講座教授 (70179547)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2012: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
|---|
| Keywords | シクロスポリン腎症 / エリスロポイエチン / カルバミル化エリスロポイエチン |
|---|
| Research Abstract |
The introduction of cyclosporine (CsA) has improved graft survival, but it causes nephropathy, which limits its clinical utility. To investigate the clinical applications of CEPO, we next evaluated the long-term therapeutic effect of CEPO using a CsA-induced nephropathy model. CsA caused renal dysfunction, while EPO/CEPO administration significantly improved renal function. EPO-treatment significantly increased Hb concentration, while CEPO-treatment neither enhanced nor reduced Hb concentration. These results suggest a new therapeutic approach using CEPO to protect kidneys from CsA-induced nephropathy.
|
Report
(4 results)
Research Products
(3 results)
-
[Journal Article] Carbamylated erythropoietin ameliorates cyclosporine nephropathy without stimulating erythropoiesis2012
Author(s)
Abe T, Isaka Y, Imamura R, Kakuta Y, Okumi M, Yazawa K, Ichimaru N, Tsuda H, Nonomura N, Takahara S, Okuyama A.
-
Journal Title
Cell Transplant
Volume: 21
Pages: 571-80
Related Report
-
-
